Today: 14 May 2026
Crocs stock today: CROX snaps back after a 6% drop as Fed minutes loom
30 December 2025
2 mins read

Crocs stock today: CROX snaps back after a 6% drop as Fed minutes loom

NEW YORK, December 30, 2025, 12:45 ET — Regular session

  • Crocs shares were modestly higher in midday trading after a steep drop a day earlier.
  • Year-end trading has been thin as investors reposition and wait on fresh signals from the Fed.
  • Focus remains on Crocs’ holiday-quarter outlook and the pace of its cost cuts.

Crocs Inc shares rose 0.6% to $86.49 in midday trading on Tuesday, stabilizing after Monday’s sharp decline. The stock fell 6.2% in the prior session and sits about 30% below its 52-week high.

The move matters because late-December liquidity can amplify swings, especially in consumer-facing names that sit at the intersection of rates and spending. Crocs has been caught in that crosscurrent after a volatile stretch into year-end.

Investors are trying to separate short-term tape action from the bigger question: whether Crocs can keep demand steady while protecting margins as it resets inventory and promotions. That debate has sharpened after management signaled a softer holiday quarter.

U.S. stocks were subdued in choppy trading on Tuesday, with gains in communication services capped by declines in tech and financials, while investors awaited minutes from the Federal Reserve’s December meeting, Reuters reported. “It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off,” said Mark Hackett, chief market strategist at Nationwide. reuters.com

That backdrop follows a down session on Monday, when Wall Street’s main indexes ended lower and the consumer discretionary sector came under pressure as Tesla slid, Reuters said. The risk-off tone left many discretionary names prone to sharp reversals as traders squared positions into the holiday.

Crocs’ most recent company update came with its third-quarter results in October. The company said revenue fell 6.2% to $996 million as wholesale sales — shipments to retailers — declined, while direct-to-consumer (DTC) revenue, from its own stores and websites, rose slightly; it also forecast fourth-quarter revenue would be down about 8% from a year earlier and projected an adjusted operating margin of about 15.5%, a profitability measure that excludes certain items.

Footwear and apparel peers were mixed on Tuesday, underscoring the stock-by-stock tone inside consumer discretionary. Nike fell 0.4% while Deckers Outdoor rose 1.7% in midday trading.

For Crocs bulls, the key is whether the company can lean harder on higher-margin DTC growth while rebuilding wholesale demand without resorting to heavy discounting. For skeptics, the HEYDUDE brand’s slump and a weaker wholesale channel remain the pressure points.

Traders have also been dealing with year-end technical flows, which can move stocks quickly without a fresh headline. In that environment, single-day drops and rebounds can say more about positioning than fundamentals.

Beyond the close, investors will keep an eye on how rate expectations evolve and whether sector leadership broadens beyond mega-cap tech. That matters for consumer names, where valuation and demand narratives can change quickly when the market’s rate story shifts.

For Crocs specifically, the next high-conviction catalyst is its next quarterly update on holiday-quarter performance and how costs are tracking against management’s savings plans. Investors will also listen for any new detail on 2026 demand trends, especially in North America.

Stock Market Today

  • Nurix Therapeutics Stock: Is Its Premium 23.3x Price-to-Sales Multiple Justified?
    May 14, 2026, 9:02 AM EDT. Nurix Therapeutics (NRIX) shares rose 1.38% to $16.18 amid mixed recent performance, down 10% year to date but up nearly 69% over one year. The stock trades at a high price-to-sales (P/S) multiple of 23.3x, well above the US biotech average of 9.7x. This premium reflects strong analyst revenue growth forecasts of 42.2% annually, outpacing the broader market. However, Nurix remains loss-making with $295 million in ongoing losses and a $1.65 billion market cap, making it vulnerable to clinical setbacks. Investors should weigh the high growth potential against risks in this early-stage biotech before assuming the premium valuation is sustainable.

Latest articles

Apple Backs Google in EU AI Fight as iPhone Rules Loom

Apple Backs Google in EU AI Fight as iPhone Rules Loom

14 May 2026
Apple warned the European Commission that proposed EU rules forcing Google’s Android to open core features to rival AI assistants could endanger privacy, security, and device performance. The Commission’s feedback period closed Wednesday, with a final decision expected by July 27. Apple argued the measures could set a precedent for its own platforms. Google also opposes the plan, calling it an “unwarranted intervention.”
Precigen Stock Jumps as Papzimeos Sales Change the Story for PGEN Investors

Precigen Stock Jumps as Papzimeos Sales Change the Story for PGEN Investors

14 May 2026
Precigen shares jumped 14.1% in early trading after first-quarter revenue reached $23.3 million, beating estimates, and net loss narrowed to $7.9 million from $54.2 million a year earlier. Papzimeos, its new RRP therapy, generated $21.6 million in net product revenue. The company ended March with $56.7 million in cash and expects current funds and Papzimeos sales to last through 2026.
POET Stock Jumps After $50 Million Lumilens AI Optics Order — The Bigger Test Comes Later

POET Stock Jumps After $50 Million Lumilens AI Optics Order — The Bigger Test Comes Later

14 May 2026
POET Technologies signed a supply and joint-development agreement with Lumilens, including a $50 million initial order for optical engines used in AI data-center networks. The companies said cumulative purchases could exceed $500 million over five years. POET shares rose 16% after the news. First engineering samples are expected in late 2026, with production targeted for 2027.
Gold Fields stock rebounds as gold steadies, with Fed minutes next
Previous Story

Gold Fields stock rebounds as gold steadies, with Fed minutes next

SSRM stock edges higher as gold rebounds — SSR Mining in focus ahead of Fed minutes
Next Story

SSRM stock edges higher as gold rebounds — SSR Mining in focus ahead of Fed minutes

Go toTop